Barrington analyst Michael Petusky raised the firm’s price target on Orthofix (OFIX) to $17 from $16 and keeps an Outperform rating on the shares. The company reported strong Q2 results and affirmed its fiscal 2025 outlook, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OFIX: